Shoulder Innovations, Inc. stock analysis
Want to see SI full AI Analyst Report?
Shoulder Innovations, Inc. (SI) Stock Price & Analysis
SI Stock Chart & Stats
- Day’s Range
- $20.56 - $21.32
- 52-Week Range
- $12.00 - $24.60
- Previous Close
- $21.08
- Volume
- N/A
- Average Volume (3M)
- 116.00K
- Market Cap
- $432.89M
- Enterprise Value
- $316.51M
- Total Cash (Recent Filing)
- $92.33M
- Total Debt (Recent Filing)
- $14.88M
- Price to Earnings (P/E)
- ―
- Beta
- -0.58
- Next Earnings
- Mar 16, 2027 (Est.)
- EPS Estimate
- -0.45
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Rapid Revenue Growth
Rapid revenue growth, supported by higher implant volumes, new surgeon additions, and increased utilization, indicates expanding adoption of the company’s shoulder platform. The raised outlook strengthens confidence that commercial momentum can persist over the next several quarters.
Strong Gross Margins
Gross margin expansion to 78.5% demonstrates attractive product economics and suggests that higher volume is not requiring broad discounting. Pricing discipline and product-cost reductions could support future contribution profit as the commercial platform scales.
Commercial And Product Adoption
Strong implant-volume growth alongside expanding surgeon adoption provides evidence of increasing utilization within the installed customer base. A deeper surgeon funnel and rising productivity per cohort can support recurring procedure growth and reinforce the platform’s market position.
Bears Say
Persistent Operating Losses
The company remains materially unprofitable, with operating expenses growing faster than revenue in the latest year. Until scale converts strong gross margins into lower losses, earnings power remains dependent on continued investment and the eventual achievement of cost discipline.
Accelerating Cash Burn
Negative operating and free cash flow show that the business is not yet self-funding despite rapid growth. Continued or worsening burn can reduce financial flexibility and increase dependence on available liquidity or future capital access while the company pursues break-even.
Ambulatory Pricing Pressure
Expansion into ambulatory surgery centers may broaden access to the shoulder market but can structurally pressure average selling prices. If ASC purchasing becomes more price-sensitive as adoption grows, it could moderate revenue quality and constrain the pace of margin improvement.
Shoulder Innovations, Inc. News
Shoulder Innovations’ Strong Q3 Execution and Raised FY2026 Outlook Support Unchanged $27 Price Target
Analyst Ryan Zimmerman of BTIG maintained a Buy rating on Shoulder Innovations, Inc., retaining the price target of $27.00. Ryan Zimmerman’s rating is based on several factors, including Shoulder Innovations’
SI FAQ
What was Shoulder Innovations, Inc.’s price range in the past 12 months?
What is Shoulder Innovations, Inc.’s market cap?
When is Shoulder Innovations, Inc.’s upcoming earnings report date?
How were Shoulder Innovations, Inc.’s earnings last quarter?
Is Shoulder Innovations, Inc. overvalued?
Does Shoulder Innovations, Inc. pay dividends?
What is Shoulder Innovations, Inc.’s EPS estimate?
How many shares outstanding does Shoulder Innovations, Inc. have?
What happened to Shoulder Innovations, Inc.’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Shoulder Innovations, Inc.?
What is the TipRanks Smart Score and how is it calculated?
Shoulder Innovations, Inc. Stock Smart Score
Company Description
Shoulder Innovations, Inc.
Shoulder Innovations, Inc. manufactures medical devices. It has developed a shoulder replacement system. The company was founded by Stephen B. Gunther and Michael DeVries in 2009 and is headquartered in Grand Rapids, MI.
- Sector
- General
- Industry
- Medical - Specialties
- CEO
- Robert Joseph Ball
- Employees
- 74
- Website
- www.shoulderinnovations.com
- Address
- 1535 Steele Avenue SW, Grand Rapids, MI, 49507, US
Shoulder Innovations, Inc. (SI) Earnings & Revenues
SI Earnings Call
Earnings Call SentimentPositive
The call was strongly positive, characterized by 38% year-over-year revenue growth, a raised full-year revenue outlook, higher gross margins, improved net and Adjusted EBITDA losses, strong surgeon additions and utilization growth, successful product launches, and substantial pipeline progress. The main challenges were expected seasonality, higher operating expenses and near-term cash burn from continued investment, lower pricing in ambulatory surgery centers, and procedure-mix effects on average selling prices. Overall, the positive operating and commercial trends significantly outweighed the disclosed challenges.
View all SI earnings summariesSI Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 11 | 6 | 5 |
| Technical Analysis | 3 | 6 | 1 |
| Moving Averages | 8 | 0 | 4 |








